Canadian Respiratory Journal / 2019 / Article / Tab 3

Research Article

Concomitant Interstitial Lung Disease with Psoriasis

Table 3

Summary of previous reports on interstitial lung disease in conjunction with psoriasis.

ReferenceAge/sexArthritisConcomitant autoimmune diseasePrior or concomitant immunosuppressant useRadiological findingPathology

Kaplan and Waite [12]70/MNoNoMTXInterstitial fibrosis with honeycombingNot specified

Guzman [10]54/MYesNoA variety of anti-inflammatory drugsConsiderable loss of volume in both upper lobes with advanced fibrosisNotable interstitial fibrosis with dilated bronchi and bronchioles

Hiki et al. [13]23/MYesIgA nephropathyNoA reticular or reticulonodular pattern with bilateral pneumonic consolidationSevere interstitial pneumonia

Salaffi et al. [14]62/MYesNoGold salts, etretinate, sulfasalazine, MTXBilateral and diffuse interstitial infiltrates, broader in the upper right lobeNot specified

Kawakami et al. [15]50/FNoPolymyalgia rheumaticNot specifiedBilateral basilar reticulonodular shadowsNSIP

Ameen et al. [16]53/FNoNoMTX, cyclosporinWidespread changes in the mid- and upper zones with thickening and nodularity of the interlobular septaeNot specified

Woltsche et al. [17]78/MYesNoSulfasalazineSmall nodular densities over both lungsLymphoplasmocytic interstitial infiltration

Manero Ruiz et al. [18]Not specifiedYesNoGold saltsNot specifiedNot specified

Tokunaga et al. [19]56/MNoNoSho-saiko-to (Chinese herbs)Microcystic lesions, reticular shadows, and traction bronchiectasis underneath the pleura at the back of both lower lobesUIP

Abou-Samra et al. [20]35/FNoNoMTX, cyclosporin, acitretinBilateral interstitial infiltrate and alveolar filling of the right pulmonary baseNot specified

Abou-Samra et al. [20]61/FNoNoAcitretin, MTXBilateral interstitial infiltrate of the pulmonary basesNot specified

Messina et al. [21]63/FNoNoNoDiffuse interstitial infiltratesObliteration of the alveolar spaces connective tissue

El-Hag et al. [22]Not specifiedNoNoInfliximab, azathioprineNot specifiedNot specified

Penizzotto et al. [23]51/FNoNoNot specifiedNot specifiedNot specified

Lee and Hutchinson [24]52/FYesNoMTX, leflunomide, sulfasalazineGround glass appearance throughout the lung fieldsNot specified

Deegan et al. [25]49/MNoNoFumaric acid estersBilateral, mostly peripheral foci of consolidation with air bronchogramsPattern of organizing pneumonia

Leger et al. [26]68/FNoNoInfliximabBilateral basal interstitial infiltrates with pleural effusionNot specified

Bale and Chee [27]67/MNoNoInfliximabPatchy alveolar and ground glass infiltratesNot specified
Kakavas et al. [28]64/MNoNoInfliximabBilateral ground glass and interstitial infiltratesNot specified

Gupta and Espiritu [29]43/FNoNoNoNSIP patternNot specified

Miyachi et al. [30]71/FNoNoEtretinate, cyclosporin, methotrexateBasal interstitial ground glass opacitiesNot specified

Deng et al. [31]30/FYesRheumatoid arthritisPrednisone, iguratimod, total glucosides of peonyNot specifiedNot specified

F: female, M: male, MTX: methotrexate, NSIP: nonspecific interstitial pneumonia, and UIP: usual interstitial pneumonia.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.